A Phase 3 interventional study of somatropin in Genetic Disorder and Noonan Syndrome, sponsored by Novo Nordisk A/S. Completed at 27 sites in Japan. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2020-08-10.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Genetic Diseases, Inborn · Novo Nordisk A/S.
Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 8 in phase 3, and was the 17th registered.
584 studies on the registry are indexed under Genetic Diseases, Inborn; 158 are open to participants now.
Browse Genetic Diseases, Inborn studies →None of the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S is open now. The open studies under Genetic Diseases, Inborn, anywhere →
Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.
This study: 3 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 41 across 306 interventional studies indexed under Genetic Diseases, Inborn.
Median enrollment 51 across the 15 interventional studies, 238 across the 8 observational. Of the 21 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of the trial is to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: somatropin
Drug: somatropin
Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
Change in Height SDS (Japanese National Reference Data)
Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 104 weeks of treatment was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline height SDS as a covariate. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the last observation carried forward (LOCF) method.
Time frame: Baseline, week 104
Height Velocity SDS
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
Time frame: Baseline to week 52
Height Velocity SDS
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
Time frame: Week 52 to week 104
Height Velocity
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days.
Time frame: Baseline to week 52
Height Velocity
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days.
Time frame: Week 52 to week 104
Incidence of Treatment Emergent Adverse Events
A treatment emergent adverse event (TEAE; for the pivotal phase) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than the date of visit 12 (104 weeks; end of pivotal phase). For withdrawal participants (if any), an adverse event with onset date no later than 7 days after the last day of NN-220 treatment was included.
Time frame: During 104 weeks of treatment
Change in IGF-I (Insulin-like Growth Factor-I)
Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 104 weeks of treatment. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in HbA1c (Glycosylated Haemoglobin)
Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 104 weeks of treatment.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Erythrocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Haemoglobin)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Haematocrit)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Neutrophils)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Lymphocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Monocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Eosinophils)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Haematology: Basophils)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)
Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL (low-density lipoprotein) cholesterol and HDL (high-density lipoprotein) cholesterol. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (r-GTP) and alkaline phosphatase. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Biochemistry: Total Protein)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Clinical Laboratory Tests (Biochemistry: Creatinine)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - creatinine. Missing values were imputed using the LOCF method.
Time frame: Baseline, Week 104
Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT
AUC (area under the curve) of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the oral glucose tolerance test (OGTT). Change from baseline results are presented as 'ratio to baseline'.
Time frame: Baseline, week 104
Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT
AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.
Time frame: Baseline, week 104
Change in Bone Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the radius, ulna and short bones (RUS) score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.
Time frame: Baseline, week 104
Change in Bone Age/Chronological Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.
Time frame: Baseline, week 104
Yearly Change in Bone Age/Change in Chronological Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from baseline (week 0) in bone age/change in chronological age was presented.
Time frame: Baseline, week 52
Yearly Change in Bone Age/Change in Chronological Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 52 in bone age/change in chronological age was presented.
Time frame: Week 52, week 104
Change in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)
Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure.
Time frame: Baseline, week 104
Change in Vital Signs (Pulse)
Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse.
Time frame: Baseline, week 104
Change in Urinalysis (Protein, Glucose and Occult Blood)
The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 104 and categorised as negative, trace, 1+, 2+ and 3+. Missing values were imputed using the LOCF method. Number of participants in each category at baseline and week 104 are presented.
Time frame: Baseline, week 104
Change in Blood Coagulation Test (Prothrombin Time and APTT)
Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: Prothrombin time and APTT (activated partial thromboplastin time). Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in ECG
The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 104 and categorised as normal, abnormal NCS (not clinically significant) or abnormal CS (clinically significant). Number of participants in each ECG category at baseline and week 104 are presented. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 104
Change in Height SDS (Japanese National Reference Data)
Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Height SDS (Noonan Syndrome Reference Data in Japanese)
Height SDS was calculated using the formula: Z=\[(value/M)\^L-1\]/(S\*L); where L, M and S are skewness (L), median (M) and coefficient of variation (S) of Japanese Noonan syndrome' height provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Height Velocity
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.
Time frame: Week 104 to week 156
Height Velocity
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.
Time frame: Week 156 to week 208
Height Velocity SDS
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
Time frame: Week 104 to week 156
Height Velocity SDS
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
Time frame: Week 156 to week 208
Incidence of Treatment Emergent AEs
A treatment emergent AE (TEAE) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than 7 days after the last day of NN-220 treatment.
Time frame: Week 0 to week 234 (208 weeks treatment period + 26 weeks extended treatment period) + 7 days (follow-up period)
Change in IGF-I
Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 208 weeks of treatment. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in HbA1c
Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 208 weeks of treatment.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Erythrocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, Week 208
Change in Clinical Laboratory Tests (Haematology: Haemoglobin)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Haematocrit)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Neutrophils)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Lymphocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Monocytes)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Eosinophils)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Haematology: Basophils)
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)
Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL cholesterol and HDL cholesterol. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - AST, ALT, r-GTP and alkaline phosphatase. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Biochemistry: Total Protein)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Clinical Laboratory Tests (Biochemistry: Creatinine)
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - creatinine. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT
AUC of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.
Time frame: Baseline, week 208
Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT
AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.
Time frame: Baseline, week 208
Change in Bone Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.
Time frame: Baseline, week 208
Change in Bone Age/Chronological Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.
Time frame: Baseline, week 208
Yearly Change in Bone Age/Change in Chronological Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 104 in bone age/change in chronological age was presented.
Time frame: Week 104, week 156
Yearly Change in Bone Age/Change in Chronological Age
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 156 in bone age/change in chronological age was presented.
Time frame: Week 156, week 208
Change in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)
Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Vital Signs (Pulse)
Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Urinalysis (Protein, Glucose and Occult Blood)
The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 208 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in Blood Coagulation Test (Prothrombin Time and APTT)
Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: prothrombin time and APTT. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
Change in ECG
The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 208 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.
Time frame: Baseline, week 208
The trial was conducted at 26 sites in Japan.
| Milestone | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Started | 25 | 26 |
| Completed | 25 | 26 |
| Not completed | 0 | 0 |
| Milestone | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Started | 25 | 26 |
| Completed | 25 | 23 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Unclassified | 0 | 1 |
| Milestone | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Started | 15 | 14 |
| Completed | 15 | 14 |
| Not completed | 0 | 0 |
Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 104 weeks of treatment was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline height SDS as a covariate. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the last observation carried forward (LOCF) method.
| Standard deviation score | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Height SDS (Japanese National Reference Data) | 0.84 ± 0.09 | 1.47 ± 0.09 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
| Standard deviation score | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity SDS | 2.80 ± 1.13 | 5.01 ± 1.92 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
| Standard deviation score | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity SDS | 0.58 ± 1.59 | 2.65 ± 1.76 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days.
| Centimeters per year (cm/year) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity | 7.88 ± 0.87 | 9.90 ± 1.49 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days.
| cm/year | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity | 6.20 ± 0.95 | 7.99 ± 1.20 |
A treatment emergent adverse event (TEAE; for the pivotal phase) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than the date of visit 12 (104 weeks; end of pivotal phase). For withdrawal participants (if any), an adverse event with onset date no later than 7 days after the last day of NN-220 treatment was included.
| Events | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events | 265 | 306 |
Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 104 weeks of treatment. Missing values were imputed using the LOCF method.
| Nanograms per milliliter (ng/mL) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in IGF-I (Insulin-like Growth Factor-I) | 90.4 ± 65.5 | 159.1 ± 88.0 |
Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 104 weeks of treatment.
| Percentage of HbA1c | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in HbA1c (Glycosylated Haemoglobin) | 0.14 ± 0.18 | 0.13 ± 0.20 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.
| 10^12 cells per liter (10^12 cells/L) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Erythrocytes) | 0.106 ± 0.300 | 0.165 ± 0.234 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.
| 10^9 cells per liter (10^9 cells/L) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Leukocytes | -0.69 ± 2.28 | -1.01 ± 1.77 |
| Thrombocytes | -6.9 ± 60.2 | -29.0 ± 63.2 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.
| Millimoles per liter (mmol/L) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Haemoglobin) | 0.26 ± 0.46 | 0.32 ± 0.55 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.
| Percentage of red blood cells | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Haematocrit) | 0.85 ± 2.11 | 0.94 ± 1.93 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.
| Percentage of neutrophils | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Neutrophils) | -4.28 ± 11.44 | 4.50 ± 9.01 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.
| Percentage of lymphocytes | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Lymphocytes) | 2.80 ± 9.07 | -4.73 ± 8.73 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.
| Percentage of monocytes | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Monocytes) | 0.38 ± 1.41 | 0.39 ± 1.35 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.
| Percentage of eosinophils | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Eosinophils) | 0.99 ± 2.95 | -0.05 ± 1.33 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.
| Percentage of basophils | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Basophils) | 0.10 ± 0.36 | -0.07 ± 0.27 |
Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL (low-density lipoprotein) cholesterol and HDL (high-density lipoprotein) cholesterol. Missing values were imputed using the LOCF method.
| mmol/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Total cholesterol | 0.073 ± 0.655 | -0.110 ± 0.371 |
| LDL cholesterol | 0.040 ± 0.521 | -0.120 ± 0.323 |
| HDL cholesterol | -0.020 ± 0.212 | -0.034 ± 0.210 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (r-GTP) and alkaline phosphatase. Missing values were imputed using the LOCF method.
| Units per liter (U/L) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| AST | -3.6 ± 2.9 | -6.0 ± 4.3 |
| ALT | -1.04 ± 3.10 | -1.73 ± 4.20 |
| r-GTP | 0.4 ± 1.6 | -3.7 ± 19.4 |
| Alkaline phosphatase | 73.8 ± 76.3 | 124.3 ± 124.0 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.
| Grams per deciliter (g/dL) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Biochemistry: Total Protein) | 0.02 ± 0.38 | -0.05 ± 0.27 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.
| mmol/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Blood urea nitrogen | -0.17 ± 0.38 | -0.21 ± 0.44 |
| Sodium | -0.3 ± 2.4 | -0.2 ± 2.6 |
| Potassium | -0.03 ± 0.32 | -0.15 ± 0.41 |
| Chloride | -0.8 ± 2.3 | -1.3 ± 1.9 |
| Total calcium | 0.00 ± 0.08 | 0.01 ± 0.07 |
| Phosphorus | 0.124 ± 0.125 | 0.129 ± 0.141 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - creatinine. Missing values were imputed using the LOCF method.
| Micromoles per liter (umol/L) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Biochemistry: Creatinine) | 1.8 ± 3.5 | 2.5 ± 3.4 |
AUC (area under the curve) of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the oral glucose tolerance test (OGTT). Change from baseline results are presented as 'ratio to baseline'.
| Ratio of AUC | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT | 0.98 ± 12.19 | 1.04 ± 17.75 |
AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.
| Ratio of AUC | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT | 1.25 ± 45.08 | 1.72 ± 85.78 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the radius, ulna and short bones (RUS) score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.
| Years | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Bone Age | 2.07 ± 0.80 | 2.63 ± 0.94 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.
| Ratio (bone age/chronological age) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Bone Age/Chronological Age | 0.047 ± 0.127 | 0.133 ± 0.127 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from baseline (week 0) in bone age/change in chronological age was presented.
| Ratio (bone age/chronological age) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Yearly Change in Bone Age/Change in Chronological Age | 0.93 ± 0.66 | 1.28 ± 0.70 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 52 in bone age/change in chronological age was presented.
| Ratio (bone age/chronological age) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Yearly Change in Bone Age/Change in Chronological Age | 1.15 ± 0.57 | 1.38 ± 0.91 |
Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure.
| Millimeters of mercury (mmHg) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Diastolic blood pressure | 2.3 ± 13.2 | 6.3 ± 15.8 |
| Systolic blood pressure | 5.5 ± 11.9 | 4.1 ± 12.1 |
Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse.
| Beats per minute (beats/min) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Vital Signs (Pulse) | -9.5 ± 15.7 | 1.8 ± 21.9 |
The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 104 and categorised as negative, trace, 1+, 2+ and 3+. Missing values were imputed using the LOCF method. Number of participants in each category at baseline and week 104 are presented.
| Participants | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Protein: Negative (Baseline) | 23 | 22 |
| Protein: Trace (Baseline) | 2 | 4 |
| Protein: 1+ (Baseline) | 0 | 0 |
| Protein: 2+ (Baseline) | 0 | 0 |
| Protein: 3+ (Baseline) | 0 | 0 |
| Protein: Negative (Week 104) | 18 | 16 |
| Protein: Trace (Week 104) | 7 | 8 |
| Protein: 1+ (Week 104) | 0 | 2 |
| Protein: 2+ (Week 104) | 0 | 0 |
| Protein: 3+ (Week 104) | 0 | 0 |
| Glucose: Negative (Baseline) | 25 | 26 |
| Glucose: Trace (Baseline) | 0 | 0 |
| Glucose: 1+ (Baseline) | 0 | 0 |
| Glucose: 2+ (Baseline) | 0 | 0 |
| Glucose: 3+ (Baseline) | 0 | 0 |
| Glucose: Negative (Week 104) | 25 | 26 |
| Glucose: Trace (Week 104) | 0 | 0 |
| Glucose: 1+ (Week 104) | 0 | 0 |
| Glucose: 2+ (Week 104) | 0 | 0 |
| Glucose: 3+ (Week 104) | 0 | 0 |
| Occult blood: Negative (Baseline) | 24 | 25 |
| Occult blood: Trace (Baseline) | 1 | 1 |
| Occult blood: 1+ (Baseline) | 0 | 0 |
| Occult blood: 2+ (Baseline) | 0 | 0 |
| Occult blood: 3+ (Baseline) | 0 | 0 |
| Occult blood: Negative (Week 104) | 25 | 20 |
| Occult blood: Trace (Week 104) | 0 | 5 |
| Occult blood: 1+ (Week 104) | 0 | 0 |
| Occult blood: 2+ (Week 104) | 0 | 1 |
| Occult blood: 3+ (Week 104) | 0 | 0 |
Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: Prothrombin time and APTT (activated partial thromboplastin time). Missing values were imputed using the LOCF method.
| Second (sec) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Prothrombin time | 0.50 (-1.8 to 2.3) | 0.80 (-0.6 to 2.3) |
| APTT | 0.60 (-4.0 to 4.7) | 0.25 (-9.1 to 5.6) |
The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 104 and categorised as normal, abnormal NCS (not clinically significant) or abnormal CS (clinically significant). Number of participants in each ECG category at baseline and week 104 are presented. Missing values were imputed using the LOCF method.
| Participants | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Normal (Baseline) | 15 | 14 |
| Abnormal NCS (Baseline) | 10 | 12 |
| Abnormal CS (Baseline) | 0 | 0 |
| Normal (Week 104) | 16 | 13 |
| Abnormal NCS (Week 104) | 9 | 13 |
| Abnormal CS (Week 104) | 0 | 0 |
Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.
| Standard deviation score | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Height SDS (Japanese National Reference Data) | 0.85 ± 0.60 | 1.84 ± 0.70 |
Height SDS was calculated using the formula: Z=\[(value/M)\^L-1\]/(S\*L); where L, M and S are skewness (L), median (M) and coefficient of variation (S) of Japanese Noonan syndrome' height provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.
| Standard deviation score | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Height SDS (Noonan Syndrome Reference Data in Japanese) | 0.96 ± 0.47 | 1.92 ± 0.60 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.
| cm/year | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity | 5.77 ± 1.26 | 7.01 ± 1.12 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.
| cm/year | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity | 5.64 ± 1.23 | 6.11 ± 1.28 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
| Standard deviation score | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity SDS | -0.39 ± 1.61 | 1.44 ± 1.25 |
Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.
| Standard deviation score | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Height Velocity SDS | -0.73 ± 1.52 | 0.92 ± 1.69 |
A treatment emergent AE (TEAE) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than 7 days after the last day of NN-220 treatment.
| Events | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Incidence of Treatment Emergent AEs | 507 | 539 |
Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 208 weeks of treatment. Missing values were imputed using the LOCF method.
| ng/mL | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in IGF-I | 133.5 ± 97.6 | 217.2 ± 91.1 |
Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 208 weeks of treatment.
| Percentage of HbA1c | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in HbA1c | 0.19 ± 0.13 | 0.20 ± 0.21 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.
| 10^12 cells/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Erythrocytes) | 0.121 ± 0.328 | 0.095 ± 0.204 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.
| 10^9 cells/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Leukocytes | -1.50 ± 2.22 | -1.50 ± 1.57 |
| Thrombocytes | -27.5 ± 55.5 | -56.6 ± 58.5 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.
| mmol/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Haemoglobin) | 0.46 ± 0.58 | 0.46 ± 0.35 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.
| Percentage of red blood cells | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Haematocrit) | 1.24 ± 2.45 | 1.26 ± 1.63 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.
| Percentage of neutrophils | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Neutrophils) | -1.23 ± 10.80 | 4.88 ± 9.41 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.
| Percentage of lymphocytes | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Lymphocytes) | -0.14 ± 8.88 | -5.70 ± 8.86 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.
| Percentage of monocytes | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Monocytes) | 0.08 ± 1.21 | 0.56 ± 1.18 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.
| Percentage of eosinophils | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Eosinophils) | 1.30 ± 3.57 | 0.42 ± 1.44 |
Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.
| Percentage of basophils | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Haematology: Basophils) | -0.01 ± 0.26 | -0.12 ± 0.26 |
Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL cholesterol and HDL cholesterol. Missing values were imputed using the LOCF method.
| mmol/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Total cholesterol | 0.031 ± 0.639 | -0.110 ± 0.609 |
| LDL cholesterol | -0.005 ± 0.550 | -0.173 ± 0.523 |
| HDL cholesterol | 0.036 ± 0.275 | 0.056 ± 0.173 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - AST, ALT, r-GTP and alkaline phosphatase. Missing values were imputed using the LOCF method.
| U/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| AST | -5.4 ± 2.4 | -7.4 ± 5.2 |
| ALT | -1.28 ± 2.65 | -1.81 ± 4.42 |
| r-GTP | 1.0 ± 1.6 | -3.5 ± 22.8 |
| Alkaline phosphatase | 113.9 ± 126.4 | 84.8 ± 140.9 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.
| g/dL | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Biochemistry: Total Protein) | 0.02 ± 0.33 | 0.05 ± 0.37 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.
| mmol/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Blood urea nitrogen | -0.10 ± 0.52 | -0.15 ± 0.53 |
| Sodium | 0.9 ± 2.1 | 1.4 ± 2.5 |
| Potassium | -0.13 ± 0.28 | -0.09 ± 0.38 |
| Chloride | -0.3 ± 2.2 | -0.2 ± 2.2 |
| Total calcium | -0.02 ± 0.07 | -0.00 ± 0.08 |
| Phosphorus | 0.036 ± 0.111 | 0.111 ± 0.103 |
Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - creatinine. Missing values were imputed using the LOCF method.
| umol/L | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Clinical Laboratory Tests (Biochemistry: Creatinine) | 5.5 ± 4.4 | 6.7 ± 4.1 |
AUC of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.
| Ratio of AUC | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT | 1.03 ± 12.34 | 1.10 ± 14.55 |
AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.
| Ratio of AUC | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT | 1.52 ± 49.97 | 2.38 ± 47.04 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.
| Years | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Bone Age | 3.89 ± 1.35 | 4.68 ± 1.11 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.
| Ratio (bone age/chronological age) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Bone Age/Chronological Age | 0.049 ± 0.159 | 0.149 ± 0.151 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 104 in bone age/change in chronological age was presented.
| Ratio (bone age/chronological age) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Yearly Change in Bone Age/Change in Chronological Age | 0.94 ± 0.70 | 0.97 ± 0.56 |
X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 156 in bone age/change in chronological age was presented.
| Ratio (bone age/chronological age) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Yearly Change in Bone Age/Change in Chronological Age | 0.87 ± 0.55 | 1.05 ± 0.51 |
Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure. Missing values were imputed using the LOCF method.
| mmHg | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Diastolic blood pressure | 5.8 ± 13.4 | 3.5 ± 8.4 |
| Systolic blood pressure | 6.8 ± 11.9 | 5.8 ± 16.1 |
Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse. Missing values were imputed using the LOCF method.
| beats/min | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Change in Vital Signs (Pulse) | -15.3 ± 14.2 | -3.8 ± 16.5 |
The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 208 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.
| Participants | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Protein: Negative (Baseline) | 23 | 22 |
| Protein: Trace (Baseline) | 2 | 4 |
| Protein: 1+ (Baseline) | 0 | 0 |
| Protein: 2+ (Baseline) | 0 | 0 |
| Protein: 3+ (Baseline) | 0 | 0 |
| Protein: Negative (Week 208) | 17 | 18 |
| Protein: Trace (Week 208) | 8 | 7 |
| Protein: 1+ (Week 208) | 0 | 0 |
| Protein: 2+ (Week 208) | 0 | 1 |
| Protein: 3+ (Week 208) | 0 | 0 |
| Glucose: Negative (Baseline) | 25 | 26 |
| Glucose: Trace (Baseline) | 0 | 0 |
| Glucose: 1+ (Baseline) | 0 | 0 |
| Glucose: 2+ (Baseline) | 0 | 0 |
| Glucose: 3+ (Baseline) | 0 | 0 |
| Glucose: Negative (Week 208) | 25 | 26 |
| Glucose: Trace (Week 208) | 0 | 0 |
| Glucose: 1+ (Week 208) | 0 | 0 |
| Glucose: 2+ (Week 208) | 0 | 0 |
| Glucose: 3+ (Week 208) | 0 | 0 |
| Occult blood: Negative (Baseline) | 24 | 25 |
| Occult blood: Trace (Baseline) | 1 | 1 |
| Occult blood: 1+ (Baseline) | 0 | 0 |
| Occult blood: 2+ (Baseline) | 0 | 0 |
| Occult blood: 3+ (Baseline) | 0 | 0 |
| Occult blood: Negative (Week 208) | 24 | 22 |
| Occult blood: Trace (Week 208) | 1 | 2 |
| Occult blood: 1+ (Week 208) | 0 | 1 |
| Occult blood: 2+ (Week 208) | 0 | 0 |
| Occult blood: 3+ (Week 208) | 0 | 1 |
Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: prothrombin time and APTT. Missing values were imputed using the LOCF method.
| sec | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Prothrombin time | 0.70 (-0.3 to 2.4) | 1.20 (-0.2 to 2.2) |
| APTT | 0.70 (-5.3 to 5.0) | 0.80 (-7.4 to 6.4) |
The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 208 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.
| Participants | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day |
|---|---|---|
| Normal (Baseline) | 15 | 14 |
| Abnormal NCS (Baseline) | 10 | 12 |
| Abnormal CS (Baseline) | 0 | 0 |
| Normal (Week 208) | 20 | 16 |
| Abnormal NCS (Week 208) | 5 | 9 |
| Abnormal CS (Week 208) | 0 | 1 |
Collected over Week 0 to week 234 (208 weeks treatment period + 26 weeks extended treatment period) + 7 days (follow-up period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.033 mg/kg/Day | 0/25 (0%) | 9/25 (36%) | 24/25 (96%) |
| 0.066 mg/kg/Day | 0/26 (0%) | 10/26 (38.5%) | 26/26 (100%) |
| Event | 0.033 mg/kg/Day | 0.066 mg/kg/Day |
|---|---|---|
| Dental cariesGastrointestinal disorders | 2/25 | 0/26 |
| Arnold-Chiari malformationCongenital, familial and genetic disorders | 1/25 | 0/26 |
| CraniosynostosisCongenital, familial and genetic disorders | 1/25 | 1/26 |
| HamartomaCongenital, familial and genetic disorders | 1/25 | 0/26 |
| Head bangingPsychiatric disorders | 1/25 | 0/26 |
| PhimosisCongenital, familial and genetic disorders | 1/25 | 0/26 |
| PneumoniaInfections and infestations | 1/25 | 0/26 |
| Pneumonia mycoplasmalInfections and infestations | 1/25 | 1/26 |
| Salivary gland calculusGastrointestinal disorders | 1/25 | 0/26 |
| Atrial fibrillationCardiac disorders | 0/25 | 1/26 |
| Event | 0.033 mg/kg/Day | 0.066 mg/kg/Day |
|---|---|---|
| NasopharyngitisInfections and infestations | 19/25 | 21/26 |
| InfluenzaInfections and infestations | 20/25 | 18/26 |
| GastroenteritisInfections and infestations | 8/25 | 14/26 |
| PyrexiaGeneral disorders | 9/25 | 9/26 |
| Upper respiratory tract infectionInfections and infestations | 8/25 | 9/26 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 7/25 | 9/26 |
| EczemaSkin and subcutaneous tissue disorders | 3/25 | 8/26 |
| Otitis mediaInfections and infestations | 7/25 | 8/26 |
| DiarrhoeaGastrointestinal disorders | 7/25 | 3/26 |
| BronchitisInfections and infestations | 4/25 | 7/26 |
Full analysis set (FAS) which included all randomised participants.
| Age, Continuous(years) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 6.57 ± 2.42 | 6.06 ± 2.25 | 6.31 ± 2.32 |
| Sex: Female, Male(Participants) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day | Total |
|---|---|---|---|
| Female | 11 | 8 | 19 |
| Male | 14 | 18 | 32 |
| Race (NIH/OMB)(Participants) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 25 | 26 | 51 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Height standard deviation score (SDS) (Japanese national reference data)(Standard deviation score) | NN-220 0.033 mg/kg/Day | NN-220 0.066 mg/kg/Day | Total |
|---|---|---|---|
| Mean | -3.24 ± 0.76 | -3.25 ± 0.71 | -3.24 ± 0.73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2013 to primary completion in Jul 2018, 58 months.
Results were first posted in Oct 2019, 1 year 3 months after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Genetic Diseases, Inborn, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 58 months is above that.
Counting every sponsor, half of 40 studies reached it within 34 months; a quarter within 24 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone